Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
To streamline complex medical writing workflows with GenAI
It is intended for contrast enhancement in MRI scans
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
Subscribe To Our Newsletter & Stay Updated
